Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABLTS:0MTD -2.19%88 Median PS Value is kr342.13 as of Jul. 14, 2026, which is 100% below its 10-year median of 0.69. GuruFocus rates LTS:0MTD with a GF Score™ of 88/100 and a GF Value™ of kr346.74 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 544 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 76.84% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Median PS Value or its related term are showing as below:
LTS:0MTD'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48 Med: 0.69 Max: 1.38
Current: 1.35
During the past 13 years, the highest Price to Median PS Value of Swedish Orphan Biovitrum AB was 1.38. The lowest was 0.48. And the median was 0.69.
LTS:0MTD's Price-to-Median-PS-Value is ranked worse than 76.84% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.875
vs LTS:0MTD: 1.35
Swedish Orphan Biovitrum AB (LTS:0MTD) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Swedish Orphan Biovitrum AB's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
460.50
/
342.13
=
1.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB Median PS Value Related Terms
Swedish Orphan Biovitrum AB Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 4.1155.
Swedish Orphan Biovitrum AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr83.133.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (LTS:0MTD) has a Median PS Value of kr342.13 as of Jul. 14, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 49484% above median its historical median of 0.69. Over the past decade, Swedish Orphan Biovitrum AB's Median PS Value has ranged from 0.48 to 1.38. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #418 out of 544 companies in the Drug Manufacturers industry, placing it in the top 76.8%.
Is Swedish Orphan Biovitrum AB's Median PS Value too high?
Swedish Orphan Biovitrum AB's current Median PS Value of kr342.13 is 49484% above median its 10-year median of 0.69. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 1.38. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #418 out of 544 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #418 out of 544 companies for Median PS Value. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median Median PS Value is 0.88. Historically, Swedish Orphan Biovitrum AB's own Median PS Value has ranged from 0.48 to 1.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.88, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Median PS Value is kr342.13, which is 49484% above median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (LTS:0MTD) is currently considered Significantly Overvalued. The stock's GF Value™ is kr346.74, compared to a current price of kr460.50 — trading 32.8% above its estimated fair value. The current Median PS Value is kr342.13, which is 49484% above median its 10-year median of 0.69. Swedish Orphan Biovitrum AB's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (LTS:0MTD), the current Median PS Value is kr342.13 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (LTS:0MTD) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of kr460.50 is trading 32.8% above its estimated GF Value™ of kr346.74.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for LTS:0MTD:
Median PS Value: kr342.13 (49484% above median its 10-year median of 0.69)
GF Value™: kr346.74 vs. price of kr460.50 (32.8% above fair value)
No single metric tells the full story. See the LTS:0MTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
88GF Score
Get the complete analysis for LTS:0MTD
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0MTD has been successfully added to your 
